Anavex Life Sciences to Present at the 10th Annual SVB Leerink Global Healthcare Conference on February 25, 2021

Rhea-AI Summary

Anavex Life Sciences Corp. (Nasdaq: AVXL) announced its participation in the 10th Annual SVB Leerink Global Healthcare Conference. Christopher U. Missling, PhD, President and CEO, will present on February 25th, 2021, at 12:00 p.m. EST, discussing the company's progress on therapeutics for neurodegenerative disorders like Alzheimer’s and Parkinson’s. The presentation will be available via webcast and can be replayed online. Anavex is known for its lead drug candidate, ANAVEX®2-73, which recently completed successful clinical trials.

NEW YORK, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, has been invited to present at the 10^th Annual SVB Leerink Global Healthcare Conference.

Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex, is scheduled to present on Thursday, February 25th, 2021 at 12:00 p.m. EST and will discuss the Company's progress and outlook.

The presentation will be webcast live and available for replay here and via the investor relations section of the Company’s website at www.anavex.com.

About Anavex Life Sciences Corp.

Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, pain and various types of cancer. Anavex’s lead drug candidate, ANAVEX^®2-73 (blarcamesine), recently completed successfully a Phase 2a clinical trial for Alzheimer’s disease and a Phase 2 proof-of-concept study in Parkinson’s disease dementia and a Phase 2 study in adult patients with Rett syndrome. ANAVEX^®2-73 is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer’s disease. ANAVEX^®2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The Michael J. Fox Foundation for Parkinson’s Research previously awarded Anavex a research grant, which fully funded a preclinical study to develop ANAVEX^®2-73 for the treatment of Parkinson’s disease. ANAVEX^®3-71, which targets sigma-1 and muscarinic receptors, is a promising clinical stage drug candidate demonstrating disease-modifying activity against the major hallmarks of Alzheimer’s disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies. In preclinical trials, ANAVEX^®3-71 has shown beneficial effects on mitochondrial dysfunction and neuroinflammation. Further information is available at www.anavex.com. You can also connect with the company on Twitter, Facebook and LinkedIn.

Forward-Looking Statements

Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks set forth in the Company’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

For Further Information:

Anavex Life Sciences Corp.
Research & Business Development
Toll-free: 1-844-689-3939
Email: info@anavex.com

Investors:
Andrew J. Barwicki
Investor Relations
Tel: 516-662-9461
Email: andrew@barwicki.com

FAQ

What is Anavex Life Sciences Corp. presenting at the SVB Leerink Global Healthcare Conference?

Anavex Life Sciences Corp. will present its progress and outlook on February 25th, 2021, during the SVB Leerink Global Healthcare Conference.

When is the Anavex Life Sciences Corp. presentation scheduled?

The presentation is scheduled for February 25th, 2021, at 12:00 p.m. EST.

What is ANAVEX®2-73 and its significance in the PR?

ANAVEX®2-73 is Anavex's lead drug candidate that has completed successful Phase 2 clinical trials for Alzheimer’s disease and Parkinson’s disease dementia.

Where can I find the Anavex presentation replay?

The presentation will be available for replay on Anavex's website after the live event.

What conditions does Anavex Life Sciences focus on?

Anavex Life Sciences develops therapeutics for neurodegenerative and neurodevelopmental disorders, including Alzheimer’s disease and Parkinson’s disease.